mFOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer: The FOCULM study
第一作者机构:[1]Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Peoples R China[2]Beijing Canc Hosp, Beijing, Peoples R China[3]First Peoples Hosp Foshan, Guangzhou, Foshan, Peoples R China[4]Sichuan Univ, West China Hosp, Chengdu, Peoples R China[5]Fujian Canc Hosp, Gastrointestinal Med Oncol, Fuzhou, Peoples R China[6]Guangdong Prov Hosp Chinese Med, Guangzhou, Peoples R China[7]Sun Yat Sen Univ, Affiliated Hosp 6, Dept Hepatobiliary Surg, Guangzhou, Peoples R China[8]Sun Yat Sen Univ, Affiliated Hosp 6, Dept Radiol, Guangzhou, Peoples R China[9]Sun Yat Sen Univ, Gastrointestinal Hosp, Guangzhou, Peoples R China[10]Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714):
Hu Huabin,Wang Kun,Wang Wei,et al.mFOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer: The FOCULM study[J].JOURNAL OF CLINICAL ONCOLOGY.2020,38(4):-.
APA:
Hu, Huabin,Wang, Kun,Wang, Wei,Qiu, Meng,Lin, Rongbo...&Deng, Yanhong.(2020).mFOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer: The FOCULM study.JOURNAL OF CLINICAL ONCOLOGY,38,(4)
MLA:
Hu, Huabin,et al."mFOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer: The FOCULM study".JOURNAL OF CLINICAL ONCOLOGY 38..4(2020):-